@article {2542,
	title = {Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy},
	journal = {Bju International},
	volume = {103},
	number = {7},
	year = {2009},
	note = {ISI Document Delivery No.: 417GSTimes Cited: 6Cited Reference Count: 37Mugabe, Clement Hadaschik, Boris A. Kainthan, Rajesh K. Brooks, Donald E. So, Alan I. Gleave, Martin E. Burt, Helen M.},
	month = {Apr},
	pages = {978-986},
	type = {Article},
	abstract = {To develop paclitaxel incorporated into unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols (dHPGs) for use as mucoadhesive intravesical agents against non-muscle-invasive bladder cancer. Two different types of dHPGs (HPG- C10-polyethylene glycol (PEG) and polyethyleneimine (PEI)-C18-HPG) were synthesized and paclitaxel was loaded into these using a solvent evaporation method. After physicochemical characterization of the resulting nanoparticles, four human bladder cancer cell lines were incubated with various concentrations of paclitaxel incorporated in dHPGs and the results were compared with those of paclitaxel formulated in Cremophor-EL (Taxol (R), Bristol-Myers-Squibb). In vivo, nude mice with orthotopic KU7-luc tumours were intravesically instilled with phosphate buffered saline, Taxol, or paclitaxel/HPG-C10-PEG. dHPGs are mucoadhesive nanoparticles with hydrodynamic radii of < 10 nm and incorporation of paclitaxel did not affect their size. The release profiles of paclitaxel from dHPGs were characterized by a rapid-release phase followed by a slower sustained-release phase. While the PEI-C18-HPG formulation released only approximate to 40\% of the initially incorporated paclitaxel, up to 80\% was released from HPG-C10-PEG. Moreover, only paclitaxel/HPG-C10-PEG was stable in acidic urine. In vitro, all paclitaxel formulations potently decreased bladder cancer proliferation although paclitaxel/HPG-C10-PEG was slightly less cytotoxic than standard Taxol. By contrast, in vivo, the mucoadhesive HPG-C10-PEG formulation of paclitaxel was significantly more effective in reducing orthotopic tumour growth than Taxol and was well tolerated. Intravesical administration of mucoadhesive nanoparticulate formulations of paclitaxel might be a promising approach for instillation therapy of patients with non-muscle-invasive bladder cancer.},
	keywords = {ARCHITECTURES, bladder cancer, chemotherapy, DESIGN, DRUG-DELIVERY, hyperbranched polyglycerols, intravesical therapy, MANAGEMENT, MICROSPHERES, MUCOADHESION, orthotopic mouse model, PACLITAXEL, pharmacokinetics, POLYMERS, unimolecular micelles},
	isbn = {1464-4096},
	url = {<Go to ISI>://000264065100022},
	author = {Mugabe, C. and Hadaschik, B. A. and Kainthan, R. K. and Brooks, D. E. and So, A. I. and Gleave, M. E. and Burt, H. M.}
}
@article {1230,
	title = {Separation of porphyrin-based photosensitizer isomers by laser-induced fluorescence capillary electrophoresis},
	journal = {Electrophoresis},
	volume = {26},
	number = {20},
	year = {2005},
	note = {ISI Document Delivery No.: 982VMTimes Cited: 3Cited Reference Count: 43},
	month = {Oct},
	pages = {3861-3868},
	type = {Article},
	abstract = {Methods for the separation of photosensitizer isomers, such as benzoporphyrin derivative monoacid, benzoporphyrin ethyl monoacid, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a, diethyleneglycol diester benzoporphyrin derivative, tin ethyl etiopurpurin, and phthalocyanine tetrasulfonate, have been systematically developed by CE. Detection was accomplished by UV absorption at 214 nm or by LIF with excitation at 442/488 nm and emission at 690 nm. The effects of three major experimental parameters of buffer types, organic solvents, and surfactant additives are described. The optimized separation conditions were determined so as to provide satisfactory separation efficiency and analysis time. The methods are shown to be suitable for the separation and determination of porphyrin and phthalocyanines regioisomers, diastereoisomers, and enantiomers.},
	keywords = {chiral additives, CHLORIN, DERIVATIVES, EFFICACY, ENANTIOMERS, FLUORESCENCE DETECTION, FRACTION, LIGHT, PANCREATIC-CANCER CELLS, PERFORMANCE LIQUID-CHROMATOGRAPHY, pharmacokinetics, PHOTODYNAMIC THERAPY, PHTHALOCYANINES, porphyrins, regioisomers},
	isbn = {0173-0835},
	url = {<Go to ISI>://000233189700008},
	author = {Peng, X. J. and Sternberg, E. and Dolphin, D.}
}
@article {757,
	title = {Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential},
	journal = {Journal of Biological Inorganic Chemistry},
	volume = {8},
	number = {1-2},
	year = {2003},
	note = {ISI Document Delivery No.: 638ACTimes Cited: 62Cited Reference Count: 52},
	month = {Jan},
	pages = {66-74},
	type = {Article},
	abstract = {A series of 2-alkyl-3-hydroxy-4-pyrone oxovanadium(IV) compounds has been synthesized, characterized, and tested for bioactivity as potential insulin-enhancing agents. The vanadyl complexes, bis(maltolato)oxovanadium(IV), BMOV, bis(ethylmaltolato)oxovanadium(IV), BEOV, and bis(isopropylmaltolato) oxovanadium(IV), BIOV, were compared against vanadyl sulfate for glucose-lowering ability, when administered i.p. to STZ-diabetic rats, at a one-time dose of 0.1 mmol kg(-1) body weight. Blood levels of vanadium were determined at regular intervals, to 72 h, following i.p. injection. All complexes tested exceeded vanadyl sulfate in glucose-lowering ability; this effect was not correlated, however, with blood vanadium levels. Analysis of the pharmacokinetics of the disappearance of [ethyl-1-C-14]BEOV after an oral gavage dose (50 mg kg(-1), 0.144 mmol kg(-1), in a 10 mL kg(-1) volume of 1\% CMC solution) indicated clearly that metal ion-ligand dissociation took place relatively soon after oral ingestion of the complex. Half-lives of fast phase uptake and slow phase disappearance for C-14 and V were calculated from a two-compartment model for whole blood, plasma, liver, kidney, bone, small intestine, and lung, ranging from 17 min (t(1/2)alpha for C-14, liver) to 30 days (t(1/2)beta for V, bone). Curves of disappearance of plasma and whole blood C-14 and V diverged dramatically within the first hour after administration of the vanadium complex.},
	keywords = {ABSORPTION, BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, CHEMISTRY, COORDINATION MODE, ETHYL MALTOL, IN-VITRO, INSULIN MIMETIC AGENT, insulin-enhancing activity, pharmacokinetics, PHOSPHATIDYLINOSITOL 3-KINASE, POLYMORPHIC FORMS, RATS, STZ-diabetic rat, vanadyl pyrone complexes},
	isbn = {0949-8257},
	url = {<Go to ISI>://000180545000008},
	author = {Thompson, K. H. and Liboiron, B. D. and Bellman, Yskdd and Setyawati, I. A. and Patrick, B. O. and Karunaratne, V. and Rawji, G. and Wheeler, J. and Sutton, K. and Bhanot, S. and Cassidy, C. and McNeill, J. H. and Yuen, V. G. and Orvig, Chris}
}
@article {2952,
	title = {PHARMACOKINETICS OF ALUMINUM 3-HYDROXYPYRIDIN-4-ONE COMPLEXES - IMPLICATIONS FOR ALUMINUM REDISTRIBUTION SUBSEQUENT TO CHELATION-THERAPY},
	journal = {Toxicology},
	volume = {92},
	number = {1-3},
	year = {1994},
	note = {ISI Document Delivery No.: PK035Times Cited: 14Cited Reference Count: 34},
	month = {Sep},
	pages = {193-202},
	type = {Article},
	abstract = {The pharmacokinetics of selected aluminum-hydroxypyridinone (Al-HP) complexes were determined in rats to better understand the relationship between their disposition and elimination parameters and the safety of HPs in the chelation therapy of Al intoxication. Five complexes were administered as i.v. bolus doses of Al-HP (0.25 mmol/kg Al-0.75 mmol/kg HP). The Al-HP steady state volumes of distribution ranged from 220 to 871 ml/kg, suggesting that each complex distributed out of the vascular compartment (which should have been approximate to 65 ml/kg). Systemic clearances ranged from 189 to 906 ml/h per kg. Elimination half-lives (t(1/2)) and mean residence times ranged from 0.36 to 0.84 and 0.52 to 1.20 h, respectively. The Al-CP20 complex had a short t(1/2) and a midrange volume of distribution. It demonstrated no apparent toxicity, whereas myoclonic seizures were observed after Al-CP22, Al-CP24 and Al-CP94 administration. The most appropriate choice for Al chelation among the HPs tested may be CP20. Characterization of the distribution and elimination of Al-HP complexes improves the understanding of potential toxicity that may be associated with HP therapy of Al intoxication.},
	keywords = {3-HYDROXY-4-PYRIDINONES, 3-HYDROXYPYRIDIN-4-ONES, aluminum, ALUMINUM CHELATION, ALUMINUM TOXICITY, CHELATION, DESFERRIOXAMINE, ENCEPHALOPATHY, gallium, INTOXICATION, INVITRO, IRON CHELATORS, OCULAR TOXICITY, pharmacokinetics, RENAL-FAILURE, SUBCUTANEOUS DEFEROXAMINE},
	isbn = {0300-483X},
	url = {<Go to ISI>://A1994PK03500015},
	author = {Allen, D. D. and Orvig, Chris and Yokel, R. A.}
}
